59.58USD-1.41%Mkt Cap: —P/E: —1d ago
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemi…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value9.86B $
Revenue (TTM)874.09M $
Gross Profit-60.60M $
Net Income (TTM)-565.17M $
Revenue/Share5.359 USD
Last Price59.58 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.5K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS4622221004
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-17.02
EV/Revenue11.29
P/S—
P/B22.26
EPS (TTM)-0.03
EPS (Forward)—
52W Range
58.0045% of range61.49
52W High61.49 USD
52W Low58.00 USD
Profitability
Gross Margin-6.93%
Oper. Margin-38.18%
EBITDA Margin-66.30%
Profit Margin-64.66%
ROE-105.50%
ROA-12.43%
Growth
Revenue Growth-40.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-496.43M $
CapEx (TTM)—
FCF Margin-39.67%
FCF Yield—
Net Debt86.67M $
Net Debt/EBITDA-0.15
Balance Sheet
Debt/Equity497.80
Current Ratio7.89
Quick Ratio6.85
Book Value/Sh2.655 USD
Cash/Share12.65 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.137.57M
Float164.85M
Insiders0.61%
Institutions110.54%
Technical
SMA 5048.72 (+22.3%)
SMA 20044.34 (+34.4%)
Beta0.40
S&P 52W Chg20.80%
Avg Vol (30d)950
Avg Vol (10d)342
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—